uniQure (QURE) to Release Earnings on Tuesday

uniQure (NASDAQ:QURE) is anticipated to release its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect uniQure to post earnings of ($0.88) per share and revenue of $4.4890 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, analysts expect uniQure to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

uniQure Stock Up 4.5%

uniQure stock traded up $0.87 during trading hours on Monday, hitting $20.00. 218,874 shares of the stock traded hands, compared to its average volume of 2,831,961. The firm’s 50-day moving average price is $16.75 and its two-hundred day moving average price is $25.53. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The company has a market cap of $1.26 billion, a PE ratio of -5.79 and a beta of 0.87. uniQure has a one year low of $8.73 and a one year high of $71.50.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on QURE. Sanford C. Bernstein cut uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Chardan Capital lifted their price objective on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.33.

Insider Transactions at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider directly owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 14,581 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the sale, the chief executive officer directly owned 660,658 shares in the company, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 49,396 shares of company stock valued at $722,734 in the last ninety days. 4.79% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of uniQure by 23.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after purchasing an additional 383,066 shares in the last quarter. Sofinnova Investments Inc. boosted its position in shares of uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after purchasing an additional 1,012,585 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new stake in shares of uniQure in the 4th quarter worth approximately $33,062,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.